Hercules Capital, Inc. $HTGC Shares Sold by JPMorgan Chase & Co.

JPMorgan Chase & Co. reduced its position in shares of Hercules Capital, Inc. (NYSE:HTGC) by 20.3% during the 3rd quarter, HoldingsChannel reports. The fund owned 419,588 shares of the financial services provider’s stock after selling 106,781 shares during the period. JPMorgan Chase & Co.’s holdings in Hercules Capital were worth $7,934,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Caitlin John LLC acquired a new position in Hercules Capital in the 3rd quarter worth about $29,000. Financial Consulate Inc. purchased a new position in Hercules Capital during the third quarter worth approximately $35,000. Orion Capital Management LLC acquired a new stake in Hercules Capital in the third quarter valued at approximately $38,000. Atlantic Union Bankshares Corp acquired a new stake in Hercules Capital in the third quarter valued at approximately $38,000. Finally, WFA of San Diego LLC purchased a new stake in shares of Hercules Capital in the second quarter valued at approximately $55,000. Hedge funds and other institutional investors own 19.69% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. Weiss Ratings downgraded Hercules Capital from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, February 24th. Wall Street Zen lowered shares of Hercules Capital from a “buy” rating to a “hold” rating in a report on Saturday, December 20th. Piper Sandler cut shares of Hercules Capital from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $20.50 to $17.50 in a research report on Friday, February 13th. Capital One Financial set a $19.75 price objective on shares of Hercules Capital in a report on Monday, December 15th. Finally, Wells Fargo & Company dropped their target price on shares of Hercules Capital from $18.00 to $17.00 and set an “overweight” rating on the stock in a research report on Friday, February 13th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $18.71.

Key Headlines Impacting Hercules Capital

Here are the key news stories impacting Hercules Capital this week:

• Positive Sentiment: Coverage noting HTGC’s intraday gain (market‑wide wrap): short item reporting the stock rose ~2.2%, which can attract momentum/contrarian buying. Hercules Capital (HTGC) Advances While Market Declines: Some Information for Investors
• Positive Sentiment: Same market‑move coverage syndicated by Zacks, reinforcing the headline momentum that may support short‑term buying interest. Hercules Capital (HTGC) Advances While Market Declines: Some Information for Investors
• Positive Sentiment: Bullish thesis pieces summarize reasons some investors like HTGC (valuation, dividend/earnings metrics) and can support longer‑term buying interest among value/income investors. Is Hercules Capital, Inc. (HTGC) A Good Stock To Buy Now?
• Neutral Sentiment: Additional bullish/analytical coverage syndicated to Yahoo/MSN summarizing the same buy case and valuation metrics — useful context but not new company‑specific catalysts. Is Hercules Capital, Inc. (HTGC) A Good Stock To Buy Now?
• Negative Sentiment: Faruqi & Faruqi notifies investors of a securities class action and May 19, 2026 deadline to seek lead plaintiff status — increases litigation risk and potential headline volatility. HTGC EQUITY ALERT: Faruqi & Faruqi, LLP Reminds Hercules Capital (HTGC) Investors of Securities Class Action Deadline on May 19, 2026
• Negative Sentiment: Levi & Korsinsky issues an investor alert about a pending securities class action naming senior officers; another direct legal risk signal that can pressure the stock. HTGC Investor Alert: Hercules Capital Securities Fraud Lawsuit – Levi & Korsinsky
• Negative Sentiment: Hagens Berman files a class action following a short‑seller report that accused the company of copying deal sourcing; the involvement of a short report plus suit amplifies reputational and disclosure risk. Hercules Capital (HTGC) Faces Securities Class Action After Short Seller Claims Company Copied Google Ventures — Hagens Berman
• Negative Sentiment: Bronstein Gewirtz Grossman and Rosen Law Firm also announce actions/alerts for the same class period — multiple firms contacting investors increases the likelihood of consolidated litigation and continued newsflow. Bronstein, Gewirtz & Grossman LLC Urges Hercules Capital, Inc. Investors to Act ROSEN, NATIONAL TRIAL COUNSEL, Encourages Hercules Capital, Inc. Investors to Secure Counsel

Insider Buying and Selling at Hercules Capital

In other Hercules Capital news, Director Thomas J. Fallon bought 20,000 shares of the company’s stock in a transaction dated Friday, February 27th. The stock was acquired at an average price of $14.20 per share, with a total value of $284,000.00. Following the completion of the acquisition, the director directly owned 150,369 shares of the company’s stock, valued at $2,135,239.80. This represents a 15.34% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Paramjeet K. Randhawa bought 3,050 shares of Hercules Capital stock in a transaction dated Wednesday, March 4th. The stock was acquired at an average price of $14.78 per share, with a total value of $45,079.00. Following the completion of the transaction, the director directly owned 19,560 shares of the company’s stock, valued at approximately $289,096.80. The trade was a 18.47% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have bought 117,015 shares of company stock valued at $1,749,620. 1.80% of the stock is owned by company insiders.

Hercules Capital Price Performance

Shares of Hercules Capital stock opened at $14.20 on Tuesday. The stock has a market capitalization of $2.61 billion, a P/E ratio of 7.76 and a beta of 0.88. The business has a 50 day simple moving average of $15.84 and a two-hundred day simple moving average of $17.44. Hercules Capital, Inc. has a 12 month low of $13.70 and a 12 month high of $19.67. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.48 and a quick ratio of 1.48.

Hercules Capital (NYSE:HTGC) last issued its quarterly earnings results on Thursday, February 12th. The financial services provider reported $0.48 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.48. Hercules Capital had a return on equity of 15.97% and a net margin of 63.80%.The firm had revenue of $133.25 million for the quarter, compared to analyst estimates of $141.57 million. During the same period in the previous year, the company posted $0.49 earnings per share. As a group, analysts predict that Hercules Capital, Inc. will post 1.96 EPS for the current fiscal year.

Hercules Capital Cuts Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, March 4th. Shareholders of record on Wednesday, February 25th were paid a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a yield of 2.0%. The ex-dividend date of this dividend was Wednesday, February 25th. Hercules Capital’s payout ratio is 87.43%.

About Hercules Capital

Hercules Capital, Inc is a specialty finance company organized as a business development company (BDC) that provides tailored debt financing solutions to high‐growth companies. Through its external management structure, Hercules Capital extends senior secured loans, subordinated debt and growth capital designed to support research and development, expansion initiatives and working capital needs. The firm primarily partners with venture capital and private equity sponsors to finance innovative enterprises across various developmental stages.

The company’s investment portfolio is concentrated in technology, life sciences and sustainable and renewable technology sectors, reflecting its focus on industries with strong growth prospects and recurring capital requirements.